CD274 and non-small cell lung carcinoma: Recently, several immune checkpoints such as the programmed cell death (PD)-1/PD-ligand 1 (PD-L1) and CTLA4 pathways have emerged as immunotherapy targets for solid tumors, particularly NSCLC, thereby improving patient survival [7].